Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Cytopathology ; 33(1): 93-99, 2022 01.
Article in English | MEDLINE | ID: covidwho-1365068

ABSTRACT

BACKGROUND: The global pandemic of the coronavirus disease 2019 represents a major concern for health services worldwide, and has also induced major changes in cytopathology practice. AIM: We aimed to verify the diagnostic performance of cytological evaluation under a new safety protocol during the pandemic compared to the standard pre-pandemic procedure. We also aimed to assess how cytological diagnoses and sampling were impacted during the pandemic period compared to the pandemic-free period in 2019. MATERIALS AND METHODS: Cytological samples of peritoneal washings taken during the first 10 months of the pandemic emergency in Italy (March 11, 2020 to January 11, 2021) were compared to samples from the preceding 10-month time frame (May 11, 2019 to March 10, 2020). RESULTS: One hundred ninety-five specimens were analysed in the present study. We observed no noticeable differences in cytological diagnoses during the pandemic period compared to the pre-pandemic period. The case numbers by diagnostic category for the pre-pandemic vs pandemic periods, respectively, were as follows: non-diagnostic, 0 vs 0 cases; negative for malignancy, 86 vs 52 cases; atypia of uncertain significance, 7 vs 1 cases; suspicious for malignancy, 0 vs 2 cases; malignant, 42 vs 4 cases. CONCLUSION: While a consistent reduction in the number of cytological examinations has been observed during the COVID-19 period, our institutional safety protocol for processing cytological samples did not affect the diagnostic reliability of peritoneal washing cytology.


Subject(s)
COVID-19/diagnosis , Cytodiagnosis , Cytological Techniques , SARS-CoV-2/pathogenicity , COVID-19/complications , Cytological Techniques/methods , Humans , Italy , Neoplasms/pathology , Specimen Handling/methods
2.
Cancer Cytopathol ; 128(12): 905-909, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-696749

ABSTRACT

BACKGROUND: Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and represents the causative agent of a potentially fatal disease. The spread of the infection and the severe clinical disease have led to the widespread adoption of social distancing measures. Special attention and efforts to protect or reduce transmission have been applied at all social levels, including health care operators. Hence, this reports focuses on the description of a new protocol for the safe management of cytological samples processed by liquid-based cytology (LBC) with an evaluation of the changes in terms of morphology and immunoreactivity. METHODS: From March 11 to April 25, 2020, 414 cytological cases suspicious for SARS-CoV-2 were processed with a new virus-inactivating method suggested by Hologic, Inc, for all LBC specimens. RESULTS: The samples showed an increased amount of fibrin in the background. A slight decrease in cellular size was also observed in comparison with the standard method of preparation. Nonetheless, the nuclear details of the neoplastic cells were well identified, and the immunoreactivity of the majority of those cells was maintained. The cell blocks did not show significant differences in morphology, immunoreactivity, or nucleic acid stability. CONCLUSIONS: Despite some minor changes in the morphology of the cells, the results of this study highlight that the adoption of the new protocol for the biosafety of LBC-processed samples in pathology laboratories is important for minimizing the risk for personnel, trainees, and cytopathologists without impairing the diagnostic efficacy of the technique.


Subject(s)
COVID-19/diagnosis , Containment of Biohazards/standards , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Laboratories, Hospital/standards , Specimen Handling/standards , COVID-19/pathology , COVID-19/prevention & control , COVID-19/transmission , Clinical Protocols/standards , Containment of Biohazards/trends , Histocytological Preparation Techniques/methods , Histocytological Preparation Techniques/standards , Humans , Laboratories, Hospital/trends , Liquid Biopsy , Pandemics/prevention & control , Pathologists/standards , Pathology, Clinical/standards , Personal Protective Equipment/standards , Risk Factors , SARS-CoV-2/isolation & purification , Specimen Handling/methods
SELECTION OF CITATIONS
SEARCH DETAIL